Frontline Treatment Selection in EGFR-Mutated NSCLC: Amivantamab-Based vs Osimertinib-Based Therapy
Thoracic oncology experts debate frontline treatment selection for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), examining clinical evidence for amivantamab + lazertinib versus osimertinib + platinum/pemetrexed. Through three patient cases, the discussion explores efficacy, high-risk disease features, and practical considerations that inform individualized treatment decisions.
Round 1
Frontline Therapy for the Newly Diagnosed Patient
The debate begins with a newly diagnosed patient with metastatic EGFR-mutated NSCLC. Panelists examine survival outcomes, durability of disease control, and mechanisms of acquired resistance, including implications for future treatment sequencing.
Round 2
Frontline Therapy for Patients With CNS Disease and Other High-Risk Features
The discussion turns to a patient with baseline central nervous system (CNS) metastases and a TP53 co-mutation. Panelists explore CNS efficacy, differences in trial assessment methods, and how high-risk disease characteristics influence treatment selection.
Round 3
Frontline Therapy Across Age and Fitness Levels
In the final round, panelists consider frontline treatment selection for an older, functionally independent patient, weighing toxicity profiles, administration approaches, supportive care, and dose modifications against treatment goals and quality of life.
©️ 2026 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
